The success of the tumor immunotherapy: neutrophils from bench to beside
The present immune therapy was focused on the immune checkpoint blockade or Chimeric Antigen Receptor T-Cell Immunotherapy (CART) transfer, but how to activate the innate immune system to antitumor still lags out. Neutrophils are the most abundant circulating leukocytes in human, and heterogeneous n...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1524038/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589846530490368 |
|---|---|
| author | Meng Zhu Ru Jia Xiaojie Zhang Pingwei Xu |
| author_facet | Meng Zhu Ru Jia Xiaojie Zhang Pingwei Xu |
| author_sort | Meng Zhu |
| collection | DOAJ |
| description | The present immune therapy was focused on the immune checkpoint blockade or Chimeric Antigen Receptor T-Cell Immunotherapy (CART) transfer, but how to activate the innate immune system to antitumor still lags out. Neutrophils are the most abundant circulating leukocytes in human, and heterogeneous neutrophils have been increasingly recognized as important players in tumor progression. They play double “edge-sward” by either supporting or suppressing the tumor growth, including driving angiogenesis, extracellular matrix remodeling to promote tumor growth, participating in antitumor adaptive immunity, or killing tumor cells directly to inhibit the tumor growth. The complex role of neutrophils in various tumors depends on the tumor microenvironment (TME) they are located, and emerging evidence has suggested that neutrophils may determine the success of tumor immunotherapy in the context of the immune checkpoint blockade, innate immune training, or drug-loaded extracellular microvesicles therapy, which makes them become an exciting target for tumor immunotherapy, but still with challenges. Here, we summarize the latest insights on how to activate neutrophils in antitumor immunity and discuss the advances of neutrophil-targeted immunotherapy strategies. |
| format | Article |
| id | doaj-art-6c61891856384d21aa5782a50ecb6169 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-6c61891856384d21aa5782a50ecb61692025-01-24T07:13:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15240381524038The success of the tumor immunotherapy: neutrophils from bench to besideMeng Zhu0Ru Jia1Xiaojie Zhang2Pingwei Xu3The First Clinical Medical College, Wenzhou Medical University, Wenzhou, Zhejiang, ChinaThe First Clinical Medical College, Wenzhou Medical University, Wenzhou, Zhejiang, ChinaDepartment of Obstetrics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaThe present immune therapy was focused on the immune checkpoint blockade or Chimeric Antigen Receptor T-Cell Immunotherapy (CART) transfer, but how to activate the innate immune system to antitumor still lags out. Neutrophils are the most abundant circulating leukocytes in human, and heterogeneous neutrophils have been increasingly recognized as important players in tumor progression. They play double “edge-sward” by either supporting or suppressing the tumor growth, including driving angiogenesis, extracellular matrix remodeling to promote tumor growth, participating in antitumor adaptive immunity, or killing tumor cells directly to inhibit the tumor growth. The complex role of neutrophils in various tumors depends on the tumor microenvironment (TME) they are located, and emerging evidence has suggested that neutrophils may determine the success of tumor immunotherapy in the context of the immune checkpoint blockade, innate immune training, or drug-loaded extracellular microvesicles therapy, which makes them become an exciting target for tumor immunotherapy, but still with challenges. Here, we summarize the latest insights on how to activate neutrophils in antitumor immunity and discuss the advances of neutrophil-targeted immunotherapy strategies.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1524038/fullneutrophilstumor immunotherapytumor cell-derived microparticlesimmune checkpointinnate immunity |
| spellingShingle | Meng Zhu Ru Jia Xiaojie Zhang Pingwei Xu The success of the tumor immunotherapy: neutrophils from bench to beside Frontiers in Immunology neutrophils tumor immunotherapy tumor cell-derived microparticles immune checkpoint innate immunity |
| title | The success of the tumor immunotherapy: neutrophils from bench to beside |
| title_full | The success of the tumor immunotherapy: neutrophils from bench to beside |
| title_fullStr | The success of the tumor immunotherapy: neutrophils from bench to beside |
| title_full_unstemmed | The success of the tumor immunotherapy: neutrophils from bench to beside |
| title_short | The success of the tumor immunotherapy: neutrophils from bench to beside |
| title_sort | success of the tumor immunotherapy neutrophils from bench to beside |
| topic | neutrophils tumor immunotherapy tumor cell-derived microparticles immune checkpoint innate immunity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1524038/full |
| work_keys_str_mv | AT mengzhu thesuccessofthetumorimmunotherapyneutrophilsfrombenchtobeside AT rujia thesuccessofthetumorimmunotherapyneutrophilsfrombenchtobeside AT xiaojiezhang thesuccessofthetumorimmunotherapyneutrophilsfrombenchtobeside AT pingweixu thesuccessofthetumorimmunotherapyneutrophilsfrombenchtobeside AT mengzhu successofthetumorimmunotherapyneutrophilsfrombenchtobeside AT rujia successofthetumorimmunotherapyneutrophilsfrombenchtobeside AT xiaojiezhang successofthetumorimmunotherapyneutrophilsfrombenchtobeside AT pingweixu successofthetumorimmunotherapyneutrophilsfrombenchtobeside |